Yahoo
NasdaqGM - Nasdaq Real Time Price USD

Connect Biopharma Holdings Limited (CNTB)

1.9650 -0.0950 (-4.61%)
As of 12:37:19 PM EDT. Market Open.
Trade CNTB on Coinbase
Chart Range Bar
Loading chart for CNTB
  • Previous Close 2.0600
  • Open 2.0600
  • Bid 1.4900 x 200
  • Ask 2.5400 x 200
  • Day's Range 1.9600 - 2.0900
  • 52 Week Range 0.9100 - 3.8200
  • Volume 80,682
  • Avg. Volume 291,661
  • Market Cap (intraday) 123.724M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.1500
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 7.07

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

www.connectbiopharm.com

64

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 6/16/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CNTB
30.32%
S&P 500 (^GSPC)
10.13%

1-Year Return

CNTB
100.51%
S&P 500 (^GSPC)
24.96%

3-Year Return

CNTB
63.75%
S&P 500 (^GSPC)
70.96%

5-Year Return

CNTB
88.69%
S&P 500 (^GSPC)
78.49%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -104.21M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-120M
-100M
-80M
-60M
-40M
-20M
0

Analyst Insights

View More

Analyst Price Targets

4.00
7.07 Average
1.9650 Current
10.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/26/2026
Analyst Canaccord Genuity
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 6

Statistics

View More

Valuation Measures

Annual
As of 6/15/2026
  • Market Cap

    129.71M

  • Enterprise Value

    84.36M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    494.74

  • Price/Book (mrq)

    3.04

  • Enterprise Value/Revenue

    362.08

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -54.20%

  • Return on Equity (ttm)

    -102.94%

  • Revenue (ttm)

    233k

  • Net Income Avi to Common (ttm)

    -64.61M

  • Diluted EPS (ttm)

    -1.1500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    46.03M

  • Total Debt/Equity (mrq)

    1.63%

  • Levered Free Cash Flow (ttm)

    -33.88M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.9650 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: